Pharmacodynamics and intubating conditions of cisatracurium in children during halothane and opioid anesthesia

Journal of Clinical Anesthesia

Volumn 12, Issue 3, 2000, Pages 173-176

  Kenaan, Charbel A ^a   Estacio, Richmond L ^a   Bikhazi, George B ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Cisatracurium; Pediatrics; Pharmacodynamics

Indexed keywords

CISATRACURIUM; FENTANYL; HALOTHANE; MIDAZOLAM; NITROUS OXIDE PLUS OXYGEN; OPIATE; THIOPENTAL;

ANESTHESIA INDUCTION; ANESTHESIOLOGICAL TECHNIQUES; ANESTHETIC RECOVERY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFANT; INTUBATION; NERVE BLOCK; NEUROMUSCULAR FUNCTION; PEDIATRIC ANESTHESIA; PHARMACODYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANESTHESIA; ATRACURIUM; CHILD; CHILD, PRESCHOOL; FENTANYL; HALOTHANE; HUMANS; INTUBATION, INTRATRACHEAL; NEUROMUSCULAR BLOCKING AGENTS; TIME FACTORS;

EID: 0034192943     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-8180(00)00132-X     Document Type: Article

References (14)

1. Kisor D.F., Schmith V.D., Wargin W.A., Lien C.A., Ornstein E., Cook D.R. Importance of the organ-independent elimination of cisatracurium. Anesth Analg. 83:1996;1065-1071.
2. Meretoja O.A., Taivainen T., Wirtavuori K. Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anesthesia. Br J Anaesth. 74:1995;6-11.
3. Brandom B.W., Woelfel S.K., Ference A., Dayal B., Cook D.R., Kerls S. Effects of cisatracurium in children during halothane-nitrous oxide anesthesia. J Clin Anesth. 10:1998;195-199.
4. 2-opioid anesthesia. Anesth Analg. 83:1996;823-829.
5. Bryson H.M., Faulds D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs. 53:1997;848-866.
6. Belmont M.R., Lien C.A., Quessy S., et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 82:1995;1139-1145.
7. Mellinghoff H., Diefenbach C. The clinical pharmacology of cisatracurium. Anaesthesist. 46:1997;481-485.
8. Glantz S.A. How to test for differences between groups. Glantz S.A., Primer of Biostatistics. 4th ed. 1997;32-64 McGraw Hill, New York.
9. Kopman A.F., Klewicka M.M., Kopman D.J., Neuman G.G. Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short and ultrashort duration. Anesthesiology. 90:1999;425-431.
10. Savarese J.J., Lien C.A., Belmont M.R., Wastila W.B. The clinical pharmacology of new benzoisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium. Anaesthesist. 46:1997;840-849.
11. Doenicke A.W., Czeslick E., Moss J., Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg. 87:1998;434-438.
12. Bluestein L.S., Stinson L.W. Jr, Lennon R.L., Quessy S.N., Wilson R.M. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation. Can J Anaesth. 43:1996;925-931.
13. Stevens J.B., Walker S.C., Fontenot J.P. The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. Anesth Analg. 85:1997;1278-1283.
14. Wulf H., Kahl M., Ledowski T. Augmentation of the neuromuscular blocking effects of cisatracurium during desflurane, sevoflurane, isoflurane or total i.v. anaesthesia. Br J Anaesth. 80:1998;308-312.